| 1.24 0.02 (1.64%) | 10-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.61 | 1-year : | 1.76 |
| Resists | First : | 1.38 | Second : | 1.51 |
| Pivot price | 1.23 |
|||
| Supports | First : | 1.16 | Second : | 0.97 |
| MAs | MA(5) : | 1.23 |
MA(20) : | 1.23  |
| MA(100) : | 1.29 |
MA(250) : | 1.3 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 42.8 |
D(3) : | 41.2 |
| RSI | RSI(14): 45.4 |
|||
| 52-week | High : | 1.91 | Low : | 0.92 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VANI ] has closed below upper band by 36.8%. Bollinger Bands are 71.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.26 - 1.27 | 1.27 - 1.27 |
| Low: | 1.21 - 1.21 | 1.21 - 1.22 |
| Close: | 1.23 - 1.24 | 1.24 - 1.25 |
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
Mon, 28 Sep 2026
Vivani Medical Inc. (NASDAQ: VANI) Share Price, VANI Stock News, VANI Share Price & Updates - Kalkine
Wed, 16 Sep 2026
Vivani Medical says Cortigent merger into ClearOne expected to price and close in October 2026 - TradingView
Thu, 03 Sep 2026
Vivani Medical to Participate in Upcoming Lake Street and H.C. Wainwright Investor Conferences - Quiver Quantitative
Thu, 16 Jul 2026
Vivani Medical director Gregg Williams buys $1m in stock - Investing.com
Tue, 14 Jul 2026
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026 - GlobeNewswire
Tue, 07 Jul 2026
Vivani Medical Enters into Agreement with Novo Nordisk to - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 90 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 55.3 (%) |
| Held by Institutions | 5.8 (%) |
| Shares Short | 530 (K) |
| Shares Short P.Month | 354 (K) |
| EPS | -0.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -48.5 % |
| Return on Equity (ttm) | -220.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -3.45 |
| PEG Ratio | 0 |
| Price to Book value | 5.9 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|